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Abstract
In 2003, a phase III placebo-controlled trial (VAX004) of a candidate HIV-1 vaccine (AIDSVAX B/B) was completed in 5,403
volunteers at high risk for HIV-1 infection from North America and the Netherlands. A total of 368 individuals became
infected with HIV-1 during the trial. The envelope glycoprotein gene (gp120) from the HIV-1 subtype B viruses infecting
349 patients was sequenced from clinical samples taken as close as possible to the time of diagnosis, rendering a ﬁnal data
set of 1,047 sequences (1,032 from North America and 15 from the Netherlands). Here, we used these data in combination
with other sequences available in public databases to assess HIV-1 variation as a function of vaccination treatment,
geographic region, race, risk behavior, and viral load. Viral samples did not show any phylogenetic structure for any of these
factors, but individuals with different viral loads showed signiﬁcant differences (P 5 0.009) in genetic diversity. The
estimated time of emergence of HIV-1 subtype B was 1966–1970. Despite the fact that the number of AIDS cases has
decreased in North America since the early 90s, HIV-1 genetic diversity seems to have remained almost constant over time.
This study represents one of the largest molecular epidemiologic surveys of viruses responsible for new HIV-1 infections in
North America and could help the selection of epidemiologically representative vaccine antigens to include in the next
generation of candidate HIV-1 vaccines.
Key words: America, demographics, gp120, HIV-1, vaccine trial.
Introduction
Over 1.2 million people are currently living with AIDS in
North America (Centers for Disease Control and Preven-
tion 2007; UNAIDS 2008). Among these, 42% are African
Americans, 40% non-Hispanic Whites, 17% Hispanic, and
1% Asian and other races. The main prevention strategy
in America is to introduce widespread testing to identify
HIV-positive people. This strategy has been successful in
some areas, such as the prevention of mother-to-child
transmission. In other areas, prevention efforts have been
less effective, and although, combination antiretroviral
treatment has helped to dramatically reduce the number
ofpeopledevelopinganddyingofAIDS,around40,000new
AIDS cases are diagnosed every year. Indeed, in the last few
years, there appears to be an increase again in the rate of
HIV-1 infection (Centers for Disease Control and Preven-
tion 2008).
Despitethesestatistics,therehavebeenfewcomprehen-
sive surveys of the viruses responsible for new (incident)
infections inNorth Americaorto monitor their population
dynamics (Flynn et al. 2005; Keele et al. 2008). Population
genetic studies will help us understand the evolutionary
history, origin, epidemiology, and population dynamics
of pathogens and, ultimately, develop improved public
health control strategies. Indeed, the emerging ﬁeld of mo-
lecular epidemiology allows researchers to deﬁne the basic
units of transmissible diseases and provides keen insights
into the past history and future directions of infectious dis-
eases (Tibayrenc 2005). A comprehensive survey of genetic
diversity of HIV-1 across North America has never before
been accomplished, yet such data are useful for the selec-
tion of representative antigens to include candidate vac-
cines and to understand the population dynamics of
HIV-1 in this area.
In 2003, a phase III placebo-controlled trial (VAX004) of
a candidate HIV-1 vaccine (AIDSVAX B/B) was completed
in individuals at high risk for HIV-1 infection (Flynn et al.
2005). The study enrolled 5,403 volunteers from North
America and the Netherlands of which 368 became in-
fected with HIV-1 despite intensive risk-reduction counsel-
ing. Envelope glycoprotein sequences were generated for
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e349 HIV-1 subtype B–infected individuals using the plasma
sample obtained closest to the time of diagnosis. A sample
of three full-length gp120 clones with open reading frames
were obtained per patient resulting in a ﬁnal data set of
1,047 sequences.
Previously, Pe ´rez-Losada et al. (2009) analyzed selective
pressure variation across races in these data, ﬁnding signif-
icant differences. In this paper, we provide a much broader
analysis of the VAX004 North American sequences in com-
bination with other sequences available in public databases
to document HIV-1 envelope glycoprotein sequence vari-
ation as a function of treatment status (vaccine or pla-
cebo), geography, race, risk group, and viral load. Here
we studied potential differences in genetic diversity due
to mutation and recombination and extend our previous
analyses on selection across races to the four other factors.
Finally, we tried to infer the demographic history of HIV-1
in North America and date the origin of the virus. The data
analyzed in this paper represent the largest molecular
epidemiologic survey of viruses responsible for new HIV-1
infections in North America and provide a unique oppor-
tunity to study HIV-1 evolution in an epidemiological
context.
Materials and Methods
VAX004 Vaccine Trial Participants
Five thousand four hundred and three volunteers were en-
rolled in the VAX004 vaccine trial and randomly assigned
to vaccine or placebo groups according to a 2:1 ratio. Ep-
idemiologic data (e.g., self-reported race, risk behavior, and
geographic location) were collected upon enrollment and
at various times during the course of the study. All subjects
were injected with AIDSVAX B/B, a bivalent vaccine pre-
pared by combining puriﬁed recombinant gp120s from
two different strains of virus (MN and GNE8) and alum
(aluminum hydroxide) adjuvant. All subjects were immu-
nized according to a 0, 1, 6, 12, 18, 24, and 30-month sched-
ule. Serum samples were collected immediately prior to
each injection and 2 weeks after each injection, with a ﬁnal
blood sample taken at 6 months following the ﬁnal injec-
tion. The specimen taken prior to each injection was used
tocalculatepreboostanti-gp120titervaluesandsubmitted
for HIV-1 testing (enzyme-linked immunosorbent assay).
The tests selected for HIV-1 testing were unaffected by
antibodies to the AIDSVAX B/B antigens. If evidence of
HIV-1infectionwasobtained,conﬁrmatorytestingwascar-
ried out by immunoblot. Once HIV-1 infections were con-
ﬁrmed, HIV-1þ subjects were enrolled in a separate
protocol (Step B) where plasma and cells were collected
at regular intervals for up to 2 years postinfection. Plasma
samples were used for viral load testing and envelope gly-
coprotein sequencing. Frozen lymphocytes were cryopre-
served for immunologic and genetic testing. The date of
infection was deﬁned as the midpoint between the last se-
ronegative specimen and the ﬁrst seropositive specimen.
The volunteers participating in the VAX004 trial were
recruited from 58 clinical sites distributed throughout
the United States, Canada, Puerto Rico, and one site in
the Netherlands. The North American participants were
distributed in ﬁve groups: Northeast, South, Southwest,
Midwest, and West (table 1). All regions included individ-
uals from the United States; the Northeast, Midwest, and
West regions included also individuals from Montreal, Tor-
onto, and Vancouver (Canada), respectively, and the South
region from Puerto Rico.
The vaccine trial protocol speciﬁed the following racial
categories: white, black, non-white Hispanic, Asian, and
‘‘other’’ (table 1). All of the ethnic data were self-reported,
and no effort was made to distinguish linguistic and geo-
graphic groups within major racial groups. The major risk
factor for infection in this trial was male homosexual trans-
mission. However, a small subgroup of subjects with other
risk factors (exchanged drugs for sex) were also included.
Although all of the trial participants were considered to be
at high risk for transmission, the protocol deﬁned relative
risk as low, medium, or high based primarily on the fre-
quency of predeﬁned high-risk behaviors. Speciﬁcally, risk
score was deﬁned as the total number of risk factors re-
ported from the following: 1) unprotected receptive anal
sex with an HIV-1–infected male partner; 2) unprotected
insertive anal sex with an HIV-1–infected male partner; 3)
unprotected receptive anal sex with an HIV-1–uninfected
male partner; 4) ﬁve acts of unprotected receptive anal sex
with a male partner of unknown HIV-1 status; 5) 10 sex
Table 1. Mean intrapatient genetic diversity (h), population
recombination rate (q), and selection (x) estimates.
HIV-1 subtype B ur v
Treatment
Placebo (122) 0.0046 5.53 1.06
Vaccine (228) 0.0042 4.55 0.90
Race
a
Asian (5) 0.0030 5.2 0.72
Black (12) 0.0052 2.15 1.45
Hispanic (22) 0.0046 3.61 0.73
Other (15) 0.0041 2.57 1.20
White (291) 0.0043 5.22 0.95
North American region
Midwest (44) 0.0039 6.26 1.06
Northeast (82) 0.0038 4.90 0.85
South (63) 0.0049 3.91 0.89
Southwest (66) 0.0046 4.97 1.11
West Coast (90) 0.0044 4.85 0.93
Risk
Low (43) 0.0045 8.54 0.99
Medium (267) 0.0044 4.23 0.98
High (58) 0.0038 5.60 0.90
Viral load categories (virions/ml)
1: <0.1 3 10
4 (16) 0.0034 2.81 0.86
2: 0.1 3 10
4 to 0.5 3 10
4 (51) 0.0031 6.82 0.81
3: 0.5 3 10
4 to 1 3 10
4 (28) 0.0038 5.40 0.94
4: 1 3 10
4 to 5 3 10
4 (75) 0.0046 4.31 0.82
5: 5 3 10
4 to 10 3 10
4 (34) 0.0040 4.71 0.90
6: 10 3 10
4 to 50 3 10
4 (69) 0.0054 4.05 1.06
7: 50 3 10
4–100 3 10
4 (15) 0.0043 4.27 1.43
8: >100 3 10
4 (12) 0.0048 4.28 0.85
NOTE.—Individuals analyzed are indicated between parentheses.
a Selection estimates were taken from Pe ´rez-Losada et al. (2009).
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418partners; 6) anal herpes; 7) hepatitis A; 8) use of poppers;
and 9) use of amphetamines. Behavioral risk scores ranged
from 0 to 7; 0 was categorized as low, 1–3 was categorized
as medium, and 4–7 was categorized as high (Flynn et al.
2005).
Viral load measurements were subdivided into eight cat-
egories for genetic analyses (table 1) ranging from  0.1  
10
4 virions/ml (category 1) to  100   10
4 (category 8).
Because of possible differences in the sequence and anti-
genic structure of viruses from early infections and late in-
fections, it was of interest to characterize the data set with
respecttotimeafterinfection.Toaccomplishthis,wecom-
pared the estimated time postinfection with viral load
measurementsdeterminedfortheﬁrstpostdiagnosisblood
draw that was collected at the same time as the specimen
used for gp120 sequence determination.
Molecular Data Sets
Three hundred and sixty-eight individuals became infected
duringthecourseofthis study,andHIV-1subtypeBviruses
from 349 of them were sequenced for the gp120 gene.
Three clones per individual were collected from the same
earliest postinfection plasma sample. A listing of the se-
quence data used for this analysis has recently been re-
leased online and can be accessed at http://www.gsid.org.
All gp120 sequences were determined using an ABI 3100 se-
quencer and assembled using Sequencher (www.genecodes.
com).
Because this study is focused on North American HIV-1
dynamics, the 15 VAX004 gp120 sequences from Dutch in-
dividuals were excluded from the analyses. From now on,
we will refer to the VAX004 North American data (1,032
sequences) as the VAX004NA data set. For the population
dynamic analyses, the VAX004NA data set was combined
with 1,010 full-length gp120 sequences from Los Alamos
(LA) (http://hiv-web.lanl.gov/content/index) and GenBank
(GB) (http://www.ncbi.nlm.nih.gov/) databases as of May
2007 togenerate theﬁnaldatasetof2,060 sequences,here-
after the VAX004NA-LAGB data set. All these sequences
corresponded to 1,218 haplotypes unevenly distributed be-
tween 1981 and 2006. Some years, such as 1985, 2004, and
2005, were overrepresented, with at least 240 haplotypes
each, but others, such as 1982, 1992, 1999, and 2001, were
represented by less than ﬁve haplotypes each. On average,
most years were represented by 10–20 haplotypes. Due to
excessive computational burden, a coalescent analysis of
population dynamics inference on the whole data set
was not attempted; therefore, we selected up to 20 haplo-
types per year that were randomly chosen three times. This
rendered three data sets of 292 haplotypes that were used
to study the past population dynamics of HIV-1 in North
America (see below).
Sequence Alignment
VAX004NA and VAX004NA-LAGB nucleotide sequences
were translated into amino acids and aligned with MAFFT
v5.7 (Katoh et al. 2005) using the global algorithm (G-INS-i)
and amino acid–speciﬁc frequencies. Questionable regions
in our amino acid alignment were identiﬁed and removed
using GBlocks v0.91b (Castresana 2000). Conserved amino
acid regions were backtranslated to nucleotides generating
an alignment of 1,401 sites for VAX004NA and 1,491 sites
for VAX004NA-LAGB. Intrapatient alignments were trivial,
so the full gp120 sequences (1,341–1,509 bp) were analyzed
for each patient.
Phylogenetic Analysis
The best-ﬁt model of DNA was selected with the Akaike
Information Criterion (Akaike 1974) as implemented in
Modeltest 3.6 (Posada and Crandall 1998). Maximum likeli-
hood phylogenetic trees were inferred using GARLI (Zwickl
2006).Nodalsupportwasassessedusingthebootstrappro-
cedure (Felsenstein 1985) with 1,000 replicates. Heuristic
searches were performed under the best-ﬁt model. In ad-
dition, Bayesian inference was performed in MrBayes 3.0
(Ronquist and Huelsenbeck 2003) using three codon-
position partitions. We ran four chains (one cold and three
heated) for 10
7 generation, sampling every 1,000 steps.
Each run was repeated four times. Convergence and mixing
of the Markov chains was assessed using Tracer v1.3
(Rambaut and Drummond 2003).
Genetic Estimators and Patient Factors
The VAX004 trial gathered individuals from different geo-
graphic, biologic, social, and racial groups, but none of
them constitute natural populations, so the genetic esti-
matescorrespondalwaystointrapatientdata,unlessother-
wise stated. Genetic diversity (h) was estimated for each
patient using a version of Watterson’s (1975) estimator
that relaxes the assumption of an inﬁnite-sites model
and is implemented in LDhat v2.0 (McVean et al. 2002).
The population recombination rate (q) was also estimated
for each patient using LDhat. Here, each analysis was re-
peated 10 times, and the q mean estimate was used for
subsequent analyses. Adaptive selection was assessed using
the ratio of nonsynonymous (dN) to synonymous (dS) sub-
stitution rates (x 5 dN/dS) and estimated in HYPHY
(Kosakovsky Pond et al. 2005) using the ﬁxed-effects likeli-
hood (Kosakovsky Pond and Frost 2005) method with tree
branch correction. Single q and h estimates were also cal-
culated for the entire VAX004NA data set.
Intrapatient q, h, and x estimates were pooled into fac-
tors (e.g., race, geographic region; table 1). Average esti-
mates were then compared across factors using the
Kruskal–Wallis test in R (R Development CoreTeam
2008). Tests based on linear models (e.g., analysis of vari-
ance) were not applied because their underlying assump-
tions were not met by some of the data sets.
Population Dynamics
Past population dynamics of HIV-1 in North America was
inferred in BEAST v1.4.2 (Drummond and Rambaut 2007)
using the Bayesian skyline plot model (Drummond et al.
2005) and a relaxed clock (lognormal) model of rate of
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clearlysuperiortoastrictclockmodelasindicatedbyBayes
factors. Relative genetic diversity through time (Nes) was
estimated directly from serial samples under the best-ﬁt
model of nucleotide substitution. The hyperparameter
m (number of grouped intervals) was set up to 1/4 of
the sequences in each data set. All output generated by
BEAST was analyzed in Tracer v1.3 to test for convergence
and mixing. We performed sixpreliminary runs for 10
7 gen-
erations under the relaxed model using the three reduced
versions (292 haploypes each) of the VAX004NA-LAGB
data set (see Molecular Data Sets). Because no noticeable
differences in parameter estimates and Bayesian skyline
plots were observed among them, we chose one data
set to perform the ﬁnal runs (2   10
7 generations).
Results
Characterization of the VAX004 HIV-1 Subtype B
gp120 Data Set
The estimated time of HIV-1 infection to ﬁrst sampling
ranged from 0 to 13 months with a mean time of infection
of 109 ± 58 days. Thus, by the criteria of Fiebig et al. (2003),
most of the sequences described in this report appear to
represent stage V and VI infections. Time-course analysis of
viral loads afterHIV-1 infection (Clark etal. 1991; Daar etal.
1991) indicate the virus replicates to a very high level (10
5–
10
6 virions/ml) within a few weeks of HIV-1 infection and
then declines to a stable setpoint value. As expected, there
was a signiﬁcant decline in mean viral loads over time
(ﬁg. 1). However, we noted a signiﬁcant compression of
the data around 3 months postinfection. This appears
to be an artifact of the 6-month interval scheduled be-
tween most clinic visits and the convention used to deﬁne
the estimated day of infection (described in VAX004 Vac-
cine Trial Participants). Therefore, the estimated date of
infection represents an overestimation, and the actual date
of infection is earlier than indicated. Because there were
approximately 20 infections with estimated dates of infec-
tion of30 days or less, we suspect that these truly represent
new and acute infections and should properly fall into
Fieberg stage II–IV infections (Fiebig et al. 2003). It is likely
that other early-stage infections occur in this cohort, but
otherassaymethodologieswillberequiredtoidentifythem.
Phylogenetic Analyses
GTRþCþI (Tavare ´ 1986) was chosen as the best-ﬁt model
for both the VAX004NA and VAX004NA-LAGB data sets
and for all their corresponding codon-position partitions.
The initial phylogenetic analyses focused on investigating
the quality of the VAX004NA data set. As expected, the
three clone sequences collected per patient clustered to-
gether and were not interdispersed with sequences from
other individuals. Although, in general, both ML and Bayes-
ian phylogenetic analyses did not reveal population struc-
turing, 17 well-supported small clades (bootstrap
proportions  70% or posterior probabilities  0.95) were
observed (ﬁg. 2). These could be transmission linkages
where individuals infected each other or were infected
by a common partner. Eleven of these clades grouped pa-
tients from different geographic areas, but the other six
clustered individuals from the same area and gender of
which ﬁve were also from the same race. Because HIV-1
infection occurs primarily in well-deﬁned risk groups, these
types of linkages are likely to be observed in studies of this
nature. Unfortunately, because information on partner re-
lationships was restricted, we could not conﬁrm the epide-
miological history of these potential transmission chains.
Thephylogenetictreesdidnotshowanyobviousclustering
of individuals based on treatment, geographic region, race,
risk, or viral load (ﬁg. 2). In fact, in all cases, individuals
within each factor seemed to be randomly distributed
across the gene trees.
FIG.1 .Characterization of gp120 sequence data set with respect to viral load and estimated time after infection. Line indicates the mean viral
load as a function of time. Plasma used for viral load testing was collected as soon as possible following diagnostic tests conﬁrming HIV-1
infection. The date of infection was deﬁned as the midpoint between the last seronegative specimen and the ﬁrst seropositive specimen.
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420FIG.2 .Maximum likelihood phylogenetic inference of North American HIV-1 subtype B population structure based on the VAX004NA data set.
Branch lengths are shown proportional to the amount of change along the branches. Clades supported by bootstrap proportions  70% or
posterior probabilities  0.95 in the Bayesian tree are shown in bold. Only one clone per patient is represented for simplicity.
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The estimates of the population mutation (h 5 0.1049)
and recombination (q 5 100) rates were extremely high
for the whole VAX004NA data set. Indeed, the average
h and q intrapatient estimates within the VAX004NA cat-
egories were much lower (table 1). Purifying selection (x ,
1)wasoperatinginmostdatasets,butevidenceofadaptive
evolution (x . 1) was also found in a few cases (table 1).
The nonparametric Kruskal–Wallis tests only indicated sig-
niﬁcant differences in h for different viral load groups
(P 5 0.009). Here, gp120 sequences from individuals be-
longing to the lower viral load categories (categories 1–
3) showed on average lower h values (0.0034) than individ-
uals belonging to higher categories (categories 6–8; h 5
0.0048).
Population Dynamics and Dating
Substitution rates per site for gp120 ranged between 0.0041
and 0.0047 (mean 5 0.0044), and the most recent com-
mon ancestor was dated in 1968 (1966–1970). The skyline
demographic plot (ﬁg. 3) suggested a rapid increase (expo-
nential growth) in Nes since the late 60s to the late 70s
followed by a horizontal phase (constant growth) since
the early 80s with three successive low inﬂections (popu-
lation decrease) 6–10 years apart. This expansion preceded
by at least 10 years the subsequent explosion of detected
HIV/AIDS cases in United States.
Discussion
Relevance of the VAX004 Data Set
ThesequencedatafromtheVAX004trial (Flynn etal. 2005;
GSID HIV-1 Data Browser; www.gsid.org/gsid_hiv_browser.
html) represents the largest survey of gp120 envelope
sequences of clade B viruses from recent infections yet as-
sembled (Flynn et al. 2005). Although the VAX004 sequen-
ces were not from acute infections, they represent a period
oftimewherevirusloadsarehighandwhereindividualsare
particularlyinfectious(Quinnetal.2000).Thesedata,along
with the acute infection data of Keele et al. (2008), provide
the basis for the selection of epidemiologically representa-
tive vaccine antigens to include in the next generation of
HIV-1 vaccines. Because sequence data from new and
recent infections have not previously been available, the
selection of vaccine antigens depended on consensus se-
quences from viruses from chronic infections. It is possible
that the lack of success of the HIV-1 vaccines tested to date
may, in part, be due to the fact that envelope proteins de-
rived from chronic infections may have different antigenic
structures than envelope proteins from transmission vi-
ruses. Several studies have reported differences in neutral-
ization sensitivity (Derdeyn et al. 2004) and structure
(Chohan et al. 2005; Jobes et al. 2006) between viruses from
new infections compared with viruses from chronic infec-
tions. Such differences may reﬂect the fact that viruses
from new infections are selected primarily for infectivity
in the absence of an effective immune response, whereas
viruses from chronic infections have undergone years of
selection to evade the immune response. Indeed, many
studies have shown that the immune response to HIV-1
needs to mature for a year or more before antibodies ca-
pable of broad cross-neutralization are detected (Richman
et al. 2003; Wei et al. 2003; Gray et al. 2007). The availability
of sequence data from new and recent infections will en-
able investigations to determine whether fundamental dif-
ferences exist in antigenic structure between viruses from
recent and chronic infections. The sequences will also en-
able the assembly ofpanels of viruses representative ofnew
and acute infections that can be used to evaluate the im-
munogenicity and potency of candidate HIV-1 vaccines.
Phylogenetic Structure of HIV-1 in North America
Our phylogenetic trees indicated that intrapatient varia-
tion was restricted compared with interpatient variation
and gave no signal of cross-contamination. According to
the gp120 phylogeny, the North American HIV-1 subtype
B population is not structured by any of the epidemiolog-
ical and clinical factors studied. This agrees with previous
results reported by Keele et al. (2008), who also showed
that viral env genes evolving from individual transmitted
or founder HIV-1 subtype B viruses generally exhibited
a star-like phylogeny. This lack of phylogenetic structuring
based on treatment is also consistent with the overall out-
come of the VAX004 trial where immunization with AIDS-
VAX B/B did not signiﬁcantly affect the rate of infection,
the viral load, the CD4 count, or the clinical outcome of
vaccinerecipientscomparedwithplaceborecipients(Flynn
et al. 2005). Given the age of the HIV-1 epidemic in North
America (AIDS was recognized in United States in 1981)
and the fact that the virus is thought to mutate at a rate
of 1% per year (Shankarappa et al. 1999; Korber et al. 2000),
the possibility existed that different clades would have
emerged in different parts of North America. But again,
our trees indicate that, contrary to what was observed
in other continents such as Africa (Tessier et al. 1993;
Papathanasopoulos et al. 2003; Peeters et al. 2003; Ferrante
et al. 2005) and Asia (Weniger et al. 1994; Oelrichs and
Crowe 2003), the North American population was homo-
geneous across the entire area of study. Although unex-
pected, this is not totally surprising considering that
individuals in developed countries travel much more than
individuals in undeveloped ones. Homogeneity across
North American HIV-1 populations was also detected by
Gilbert et al. (2007) in their study of the emergence of
HIV-1 in the Americas. Phylogenetic differences based
on risk factors have been observed in Thailand where
the prevalent viruses among people infected through het-
erosexual transmission are predominately Clade A/E,
whereas in intravenous drug users, both Clade A/E and
CladeB viruses are incocirculation (Ouetal.1993; Weniger
et al. 1994). This does not seem to be the case in North
America, where the predominant strain among homosex-
uals and those who exchanged drugs for sex is HIV-1 sub-
type B (Centers for Disease Control and Prevention 2007;
UNAIDS 2008).
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No signiﬁcant differences in recombination, mutation, and
selection rates were observed among vaccinated and pla-
cebo individuals, risk behavior, or samples from different
geographicregions;butlowerviralloadwasassociatedwith
lower mutation rates. Because genetic diversity is positively
correlatedwithNe,onecouldexpectthatgreaterviralloads
(census size) would also cause an increase on the number
of effective virions. Signiﬁcant differences in selection pres-
sure (x) among races were detected by Pe ´rez-Losada et al.
(2009) using these same data, suggesting that immune re-
sponse induced by HIV-1 is stronger in black than in white
volunteers. If additional data conﬁrm that HIV-1 evolution
is impacted by ethnic background or viral load, investigat-
ing the genetic determinants of these differences should
become a public healthpriority. Future HIV-1 vaccine stud-
ies and trials need to make an effort to include a broader
representationofvolunteerssothesefactorscanbeallcon-
sidered.
Demographics and Dating of HIV-1 in North
America
Our coalescent estimate of the time of emergence of HIV-1
subtype B using North American samples was 1968 (1966–
1970).Thisestimatecorrespondstothatofthe‘‘pandemic’’
clade in Gilbert et al. (2007), which encompasses the vast
majority of non-Haitian subtype B infections in the United
States and elsewhere around the world and that was dated
as 1969 (1966–1972). Both studies then suggest that HIV-1
wascirculatingcrypticallyinNorthAmericafor11–15years
before the ﬁrst cases of HIV/AIDS were recognized in
United States in 1981. As indicated in Gilbert et al.
(2007), this dating is supported by serological evidence
from studies performed in 1978 in New York (Stevens
et al. 1986) and San Francisco (Jaffe et al. 1985), which sug-
gestthatthevirushadbeenspreadinginthemenwhohave
sex with men (MSM) population for several years before
this point. Even more, our analysis of subtype B past
dynamics also suggests that viral populations have already
greatly expanded before the number of detected AIDS
cases exploded in the 80s when the virus entered the high-
est riskMSMpopulation, and that, despitethe fact that the
number of AIDS cases has decreased by about 50% since
the early 90s (http://www.cdc.gov/hiv/), HIV-1 relative ge-
neticdiversityhasremainedalmostconstantandinvariably
high (ﬁg. 3). This is particularly important because under
circumstances of high HIV-1 diversity and low surveillance,
new (recombinant or mutant) or existing infective strains
could expand exponentially. Coincidentally with this result,
in the last few years, an increase in the rate of HIV-1 infec-
tion has been observed (Centers for Disease Control and
Prevention 2008). These two observations then suggest
thatNorthAmericaneedstostrengthenpreventionefforts,
especially among high-risk groups such as MSM and inject-
ing drug users, but also among the general population to
avoid AIDS resurgence.
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